ADAURA

一行要約

切除可能 stage IB-IIIA EGFR 変異 NSCLC (ex19del / L858R) への adjuvant Osimertinib 3 年 vs Placebo の phase III。DFS HR 0.20 / OS HR 0.49 で EGFR+ NSCLC adjuvant 標準を確立、driver targeted adjuvant の paradigm を切り開いた。ALINA (ALK Alectinib adjuvant) の先駆。

試験デザイン

• 対象: Stage IB-IIIA NSCLC、完全切除後、EGFR ex19del または L858R、adjuvant 化療済 or omitted、N=682
• 介入群 (n=339) : Osimertinib 80mg/day × 3 years
• 対照群 (n=343) : Placebo × 3 years
• 層別化: 病期 (IB / II / IIIA)、変異タイプ、人種

主要結果

• DFS (primary, Stage II-IIIA) : HR 0.17 (95% CI 0.11–0.26)、median NR vs 19.6 mo
• DFS (overall, Stage IB-IIIA) : HR 0.20 (95% CI 0.14–0.30)
• OS (NEJM 2023 Tsuboi) : HR 0.49 (95.03% CI 0.34–0.70, p<0.001)、5-yr OS 88% vs 78%
• CNS DFS: HR 0.18 (CNS 再発リスク 82% 低下)
• AE: Grade ≥3 23% vs 14%、皮疹・下痢・QTc 延長が増加

臨床的意義

• Stage IB-IIIA EGFR+ NSCLC adjuvant の global standard を Osimertinib 3 年に
• CNS 再発抑制 — micrometastasis での brain seeding 制御
• Driver targeted adjuvant paradigm: ALINA (Alectinib) / LIBRETTO-432 (Selpercatinib) / ALEC-Adj 系列へ波及
• 議論: 治療期間 3 年は妥当か、shorter duration (1-2 年) 試験がない、cure 比率 vs delaying recurrence の理論的解釈

Open Questions

• 3 年治療期間の妥当性: shorter duration / treatment-free interval の prospective 試験
• Cure fraction vs delayed recurrence: long-term plateau の確認、再発時の TKI rechallenge response
• MRD-guided treatment escalation/de-escalation: ctDNA-based personalization (NEOLAUNCH 等)
• Stage IA への拡張: ADAURA は IA 除外、smaller tumor での efficacy 不明
• EGFR ex20ins / 稀少 variant への adjuvant: 別 trial design

重要論文 Top 10

1. ★★★★★ Wu et al. NEnglJMed 2020 — ADAURA primary publication (DFS)
2. ★★★★★ Wu et al. NEnglJMed 2020 — ESMO presentation 詳細
3. NEJM-2023-Tsuboi-Overall survival with osimertinib in resected EGFR-mutated NSCLC — OS confirmatory (HR 0.49)
4. ★★★★ Soria et al. NEnglJMed 2018 — FLAURA — 1L echo paradigm
5. NEJM-2024-Lu-Aumolertinib as adjuvant therapy in EGFR-mutated resected NSCLC — 中国 Aumolertinib echo (regional alternative)

関連エンティティ

• 薬剤クラス: EGFR-TKI (Osimertinib)
• 遺伝子: EGFR
• 関連試験: FLAURA / LAURA / FLAURA2
• ドメイン: lung-cancer-treatment

関連論文

Basic-Liquid-biopsy

• Xia et al. ClinCancerRes 2022 — Perioperative ctDNA-based molecular residual disease detection for non-small cell lung cancer A prospective multicenter

Basic-Oncogene and genetics

• Liu et al. SciTranslMed 2022 — A germline SNP in BRMS1 predisposes patients with lung adenocarcinoma to metastasis and can be ameliorated by targeting

Basic-Others

• Osarogiagbon et al. AmSocClinOncolEducBook 2026 — Optimal use of targeted therapy and immunotherapy in early-stage, resectable non-small cell lung cancer

Clinical-Epidemiology

• Potter et al. AnnThoracSurg 2023 — Recurrence after complete resection for non-small cell lung cancer in the national lung screening trial
• Fick et al. JThoracCardiovascSurg 2025 — Late recurrence of completely resected stage I to IIIA lung adenocarcinoma
• Thai et al. Lancet 2021 — Lung Cancer

Clinical-NSCLC-Driver negative

• Wada et al. EurJCardiothoracSurg 1999 — Postoperative adjuvant chemotherapy with PVM (cisplatin + vindesine + mitomycin C) and UFT (uracil + tegaful) in
• Pathak et al. JAMAOncol 2020 — Association of survival with adjuvant chemotherapy among patients with early-stage non-small cell lung cancer with vs
• Strauss et al. JClinOncol 2008 — Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer CALGB 9633 with
• Arriagada et al. JClinOncol 2010 — Long-term results of the international adjuvant lung cancer trial evaluating adjuvant cisplatin-based chemotherapy in
• Kenmotsu et al. JClinOncol 2020 — Randomized phase III study of pemetrexed plus cisplatin versus vinorelbine plus cisplatin for completely resected stage
• Fick et al. JThoracCardiovascSurg 2025 — High-risk features associated with recurrence in stage I lung adenocarcinoma
• Felip et al. Lancet 2021 — Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010) a
• Park et al. LungCancer 2019 — A phase ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs
• Wang et al. NatMed 2021 — Toward personalized treatment approaches for non-small-cell lung cancer

Clinical-NSCLC-Driver-Other

• Jones et al. ClinCancerRes 2021 — KRAS G12C mutation is associated with increased risk of recurrence in surgically resected lung adenocarcinoma
• Finn et al. JThoracOncol 2021 — Prognostic impact of KRAS G12C mutation in patients with NSCLC results from the european thoracic oncology platform
• Wu et al. NEnglJMed 2026 — Selpercatinib in early-stage RET fusion-positive non-small-cell lung cancer
• Caswell et al. TrendsCancer 2026 — Lung cancer in never smokers from early detection to prevention

Clinical-NSCLC-EGFR

• Zhao et al. CancerTreatRev 2026 — Perioperative strategies for resectable EGFR-mutant NSCLC evidence hierarchy and clinical decision-making
• Heon et al. ClinCancerRes 2010 — Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR
• Kelly et al. JClinOncol 2015 — Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non-small-cell lung cancer (RADIANT) A randomized,
• Zhong et al. LancetOncol 2018 — Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC
• Wu et al. NEnglJMed 2020 — Osimertinib in resected EGFR-mutated non-small-cell lung cancer
• Pao et al. ProcNatlAcadSciUSA 2004 — EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors